Research Paper Reviews
A close reading of SELECT: the hazard ratio and the people who stopped
The cardiovascular benefit and the discontinuation rate are in the same paper. Quoting one without the other changes the result.
SELECT is often reduced to a single relative reduction. The paper by Lincoff and colleagues is more specific. Weekly semaglutide 2.4 mg, in adults with cardiovascular disease and overweight or obesity and without diabetes, was compared with placebo. The primary composite happened in 6.5 percent versus 8.0 percent. The hazard ratio was 0.80.
The sentence next to it
Permanent discontinuation for adverse events was 16.6 percent on semaglutide and 8.2 percent on placebo. That is not a footnote from a different study. It is a result of this randomization, over a mean follow-up of 39.8 months, in 17,604 patients. A summary that prints the hazard ratio and drops the discontinuation rate is editorializing by omission.
What a close reading refuses
The review does not convert 2.4 mg weekly into a smaller research dose. It does not move the result into people with diabetes; FLOW asked that question separately, at 1 mg. It does not treat an abstract’s first percentage as the only analysis in the tables. The DOI is the text this note is reading.